Evidence map›Paper›PMID 35784363›Full record

ArticleFrontiers in immunology2022

Comprehensive Evaluation of the m

Mingke Yu, Xuefei Liu, Han Xu, Sangyu Shen, Fajiu Wang, Dajin Chen, Guorong Li, Zongping Wang, Zhixiang Zuo, An Zhao

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05705583 (A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05705583 unknown statusnot on this mapstarted 2023, after this paper: background citation

A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma

TypeobservationalSponsorZhejiang Cancer HospitalRan2023 to 2025Enrolled100ConditionsRenal Cell CarcinomaArmsOther: Blood and Urine Collection
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. The roles and implications of RNA mNature reviews. Clinical oncology · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Mingke YuExperimental Research Center, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Xuefei LiuState Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Han XuDepartment of Pediatrics, The Affiliated Children's Hospital of Nanchang University (Jiangxi Provincial Children's Hospital), Nanchang, China.
Sangyu ShenThe Second School of Clinical Medicine , Zhejiang Chinese Medical University, Hangzhou, China.
Fajiu WangDepartment of Cardiothoracic Surgery, Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Dajin ChenKidney Disease Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Guorong LiDepartment of Urology, North Hospital, Centre Hospitalier Universitaire (CHU) of Saint-Etienne, University of Jean-Monnet, Saint-Etienne, France.
Zongping WangDepartment of Urology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Zhixiang ZuoState Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
An ZhaoExperimental Research Center, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
University of Chinese Academy of Sciences · CNCentre Hospitalier Universitaire de Saint-Étienne · FRChinese Academy of Sciences · CNNanchang University · CNSun Yat-sen University · CNSun Yat-sen University Cancer Center · CNZhejiang Cancer Hospital · CNZhejiang Chinese Medical University · CNZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is known for its high drug resistance. The tumor-immune crosstalk mediated by the epigenetic regulation of N6-methyladenosine (m Methods: This study comprehensively analyzed m Results: The expressional alteration landscape of m Conclusions: The proposed MRPRS is a promising biomarker to predict clinical outcomes and therapeutic responses in ccRCC patients.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorEpigenesis, GeneticHumansImmunologic FactorsImmunotherapyPrognosisRisk FactorsBiomarkers, TumorImmunologic Factorsclear cell renal cell carcinomaimmune infiltration characteristicimmunotherapymutationN6-methyladenosineprognosis

Identifiers

PMID35784363
PMCPMC9248360
OpenAlexW4283080378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.